Vytorin® (ezetimibe/simvastatin) – First-time generic
April 26, 2017 – Impax and Teva announced the FDA approval and immediate launch of generic versions of Merck’s Vytorin (ezetimibe/simvastatin) for the treatment of primary hyperlipidemia and homozygous familial hypercholesterolemia.
Download PDF
